Alexandria Wyckoff
Reality star Savannah Chrisley was recently under the federal spotlight for her new company, GoodGirlRx.
The U.S. Food and Drug Administration (FDA) took issue with some of the wording on her weight-loss medicine, warning her about making false and misleading claims about GLP-1s.
Feds Warn Savannah Chrisley
According to TMZ, the feds sent a warning letter to Savannah Chrisley last month. They told Chrisley that they reviewed her website, GoodGirlRx, and found some issues.
GoodGirlRx was founded by Chrisley and is a “wellness company” that provides “science-backed care designed to support the way women actually live.”
The problems were specifically surrounding the GLP-1s on her site.
The GLP-1 products on her site containing semaglutide and tirzepatide were particular sore points with the FDA, since she used the phrases “FDA-approved meds,” “FDA-approved options,” and “clinically proven GLP-1 results” alongside the products.
These compounded drug products are not FDA-approved.
They also didn’t care for Chrisley implying her products had been “evaluated for safety and effectiveness when they have not.”
Savannah Chrisley was warned she was in violation of federal law and was then given 15 business days to make corrections to her site. If she failed to do so, she risked legal action.
Changes to Her Site
It seems that Savannah Chrisley took the warning seriously, as several changes to her website have already been made to comply with the FDA’s rules.
For instance, the phrasing now says “clinically studied results,” not “clinically proven.”
She has also included disclaimers to the product, stating the GLP-1 drugs are not FDA-approved.
While it may seem like small changes, they are a big difference to the FDA and their guidelines.
Chrisley Speaks Out
Savannah Chrisley later spoke to TMZ about the change, stating:
“This was about website wording, not patient safety. There were no fines and no disciplinary action. We’re proud to help women access licensed physicians and we welcome the FDA’s guidance.”